Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hyper-leukocytosis > 50.109/L is observed in 15% of acute myeloid leukemia (AML).
Level of hyper-leukocytosis is linearly associated with the incidence of life threatening complications that lead to the early death in 25% of these patients.
The HEAL project is a prospective, uni-centric, observational study that plans to include a cohort of 50 patients presenting de novo AML with hyper-leukocytosis (HL) (> 50.109/L) and 10 controls. The aim of the study is to describe the relative proportion of various hemostasis components disturbances, endothelium alterations, platelet dysfunction and to calculate cumulative incidence of hemorrhagic and thrombotic complications as well as overall survival of patients presenting with HL AML.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cases | Patients with acute myeloid leukemia, associated to hyper leukocytosis | ||
| Control | Patients with acute myeloid leukemia, without hyper leukocytosis |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of ICAM- | plasma concentration of ICAM- | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction parameter assessed by plasma concentration of Syndecan-1 | plasma concentration of Syndecan-1 | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction parameter assessed by plasma concentration of vWF Ag | plasma concentration of vWF Ag | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by vWF activity | vWF activity | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Fg | plasma concentration of Fg | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of t-PA | plasma concentration of t-PA | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of u-PA | plasma concentration of u-PA | 12hours after chemotherapy initiation |
| Measure | Description | Time Frame |
|---|---|---|
| Cumulative incidence of serious bleeding events | Time from inclusion to first serious bleeding event | 1 month |
| Cumulative incidence of thrombotic events | Time from inclusion to first thrombotic event |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with acute myleoid leukemia associated to hyper-leukocytosis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015470 | Leukemia, Myeloid, Acute |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of e-Selectin | plasma concentration of e-Selectin | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of sCD40L | plasma concentration of sCD40L | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction parameter assessed by plasma concentration of IL6 | plasma concentration of IL6 | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of AT | plasma concentration of AT | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Fragments thrombin 1+2 | plasma concentration of Fragments thrombin 1+2 | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of TAT complex | plasma concentration of TAT complex | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of plasmin-antiplasmin complex | plasma concentration of plasmin-antiplasmin complex | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of PAI-1 Ag | plasma concentration of PAI-1 Ag | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of PAI-1 activity | plasma concentration of PAI-1 activity | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of t-PA-PAI-1 complex | plasma concentration of t-PA-PAI-1 complex | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of ADAMTS13 Ag | plasma concentration of ADAMTS13 Ag | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by ADAMTS13 activity | ADAMTS13 activity | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of vWF:CB | plasma concentration of vWF:CB | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Fibrin monomers | plasma concentration of Fibrin monomers | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by Prothrombine Time | Prothrombine Time | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by Activated Partial Thromboplastin Time [APTT] | Activated Partial Thromboplastin Time [APTT] | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Factor IX | plasma concentration of Factor IX | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Factor II | plasma concentration of Factor II | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Factor VIII | plasma concentration of Factor VIII | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Factor XII | plasma concentration of Factor XII | 12hours after chemotherapy initiation |
| Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Factor X | plasma concentration of Factor X | 12hours after chemotherapy initiation |
| 1 month |
| Overall survival | Time from inclusion to death of any cause | 1 month |
| ICU length of stay | duration of stay in ICU within the first month | 1 month |
| D006402 |
| Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |